PE
PVLA

Point72 Europe’s Palvella Therapeutics PVLA Stock Holding History

Point72 Europe’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$728 Buy
+12
New +$535 ﹤0.01% 698

Other funds holding PVLA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Point72 Europe's PVLA Position: Q3 2025 in Review

Point72 Europe opened a new position in Palvella Therapeutics (PVLA) in Q3 2025: 12 shares worth $728. The stake represents ﹤0.01% of the portfolio and ranks #698 among its holdings.

100 funds tracked by Wall St. Rank hold PVLA as of Q3 2025.

  • Point72 Europe held 12 shares of Palvella Therapeutics worth $728 as of Q3 2025.
  • Palvella Therapeutics was a new Point72 Europe position in Q3 2025.
  • Palvella Therapeutics made up ﹤0.01% of Point72 Europe's portfolio in Q3 2025, its #698 holding.
  • 100 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q3 2025.

Based on Point72 Europe's 13F filing for Q3 2025, filed 14 Nov 2025.